2024
High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine
Ottesen T, Wickersham J, Lawrence J, Antoniak S, Zezuilin O, Polonsky M, Antonyak S, Rozanova J, Dvoriak S, Pykalo I, Filippovych M, Altice F. High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine. PLOS ONE 2024, 19: e0305086. PMID: 39028735, PMCID: PMC11259278, DOI: 10.1371/journal.pone.0305086.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy prescriptionAntiretroviral therapyCD4 countSubstance use disordersIncreased levels of stigmaNational sampleLevel of stigmaIndependent of risk groupSuboptimal antiretroviral therapyInitiate antiretroviral therapyPopulation of peopleHIV expertsHIV incidenceHIV physiciansHIV treatmentKey populationsTransgender womenAntiretroviral treatmentFeeling thermometerDrinking alcoholSex workersPhysiciansSex partnersPWHRisk groups
2021
HIV care continuum among cisgender and transgender women sex workers in Greater Kuala Lumpur, Malaysia
Ranjit YS, Gibson BA, Altice FL, Kamarulzaman A, Azwa I, Wickersham JA. HIV care continuum among cisgender and transgender women sex workers in Greater Kuala Lumpur, Malaysia. AIDS Care 2021, 35: 784-790. PMID: 34723714, PMCID: PMC9056582, DOI: 10.1080/09540121.2021.1995839.Peer-Reviewed Original ResearchConceptsTransgender women sex workersHIV care continuumAntiretroviral treatmentSex workersCare continuumWomen sex workersTransgender womenImportant key populationProportion of womenRespondent-driven sampling studyEvidence-based strategiesAntiretroviral therapyHIV careHIV prevalenceHIV epidemicHIVKey populationsWomenKuala LumpurCisgender womenCount testUnique needsSmall proportionTherapyPopulation
2012
Early Identification of HIV: Empirical Support for Jail-Based Screening
de Voux A, Spaulding AC, Beckwith C, Avery A, Williams C, Messina LC, Ball S, Altice FL. Early Identification of HIV: Empirical Support for Jail-Based Screening. PLOS ONE 2012, 7: e37603. PMID: 22662177, PMCID: PMC3360747, DOI: 10.1371/journal.pone.0037603.Peer-Reviewed Original ResearchConceptsAntiretroviral treatmentClient-level dataCD4 countHIV testingMedian CD4 countRoutine HIV testingInitial CD4 countTime of diagnosisInjection drug useYounger median ageUnprotected anal intercourseCross-sectional analysisAntiretroviral therapyMedian agePharmacy costsDisease progressionAnal intercoursePost dischargeSubset of individualsNew diagnosisDrug useEarly identificationDiagnosisCells/Baseline data
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatment
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals